Intravenous thrombolytic therapy for acute ischemic stroke. Weighing the risks and benefits of tissue plasminogen activator.
The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral hemorrhage. To decrease the risk, tPA use must be restricted to a carefully selected patient population. Treatment must be administered in an intensive care setting and directed by physicians with expertise in diagnosing and managing stroke.